Comparable Company Analysis: Elanco Animal Health Incorporated (ELAN), Hi-Crush Inc. (HCR)

You should consider shares of Elanco Animal Health Incorporated (NYSE:ELAN) and Hi-Crush Inc. (NYSE:HCR) if you are looking for a great stocks to invest in. Starting with the ELAN shares, which traded at $27.30 at the close of the recent session, dropping -1.16%. On Tuesday, the company’s shares shed -$0.32 from its value which represented in intraday trading. The stock is now -18.29% lower in year-to-date (YTD) trading. ELAN’s intraday high was $27.48 while its lowest price touched $27.00. The stock’s 52-week high price is $35.46, which means the current price is at -23.01%. In terms of trading activity, the daily trading volume fell to 1472301 against 200-day average trading volume of 5,563,768 shares.

What are analyst forecasts for Elanco Animal Health Incorporated (NYSE:ELAN)?

At a consensus rating of 4.10, ELAN is trending as a streaking Moderate Buy, as it has been the case a month ago when 11 analysts called it a Moderate Buy. Two months ago, 13 analysts recommended, on average, that ELAN stock is a Moderate Buy. The Technology company’s shares’ overall bearish trend saw it close higher on Tuesday compared to its opening price of $27.19 on the day.

Forecasts for Elanco Animal Health Incorporated (NYSE:ELAN) give the stock a fair value for the growth of 14.69% from its last price. The 12-month price forecast for the stock by analysts puts the stock’s mean price target at $32.00, which means the price per share could rise by nearly $4.7. The price range target is between a low of $28.00 and a high of $38.00. The stock would need to gain by about $28.16 to hit the estimated high or 0.92% from its 12-month low.

The consensus among 12 analysts is that it is a good time for one to Overweight in the Elanco Animal Health Incorporated. 7 analysts rate ELAN as a Buy, with 0 of 12 analysts rate it as a Sell. 0 have valued the stock as Overweight and 5 have recommended that investors Hold.

Elanco Animal Health Incorporated (NYSE:ELAN) Upgrades and Downgrades

In terms of rating changes, Morgan Stanley on November 07, 2019, Upgrade Elanco Animal Health Incorporated (ELAN) at Overweight. They believe the stock could reach $32 in the near term. Analysts at Barclays have assigned a Overweight rating for the stock in their research note on September 23, 2019 with an estimated price target of $36. Moreover, BofA/Merrill analysts issued a rating of Neutral for the stock on August 26, 2019, giving it a price target of $30 for the next 12 months. On August 15, 2019, the stock earned a Neutral rating due to an analyst call from UBS, while analysts from Guggenheim on May 23, 2019 suggested that the stock is Neutral.

Hi-Crush Inc. (NYSE:HCR) adds -$0.06 on Tuesday

The HCR stock has tanked -80.89% year-to-date and is currently trading at $0.68, which is -88.87% below its 52-week high. The company shares lost -7.55% on the day and have risen nearly 2.10% off a low hit. At current levels, Hi-Crush Inc. has a valuation of about $673.10M. As of 12/03/19, this stock has fallen -16.92% during the week and closed at $0.74 in the previous session. However, recent Hi-Crush Inc. stock performance shows that HCR shares are -44.38% down over the last month, and -51.14% down for the last three months.

Earnings per share (EPS) estimates for the current quarter are -$0.07, with the trailing 12-month share earnings at -$4.04. The ratio is expected to be down by -118.30% for the current year 2019 and -19.20% for next year. Over the next 5-year period, earnings per share will be -1.42%. But will the HCR stock surprise in the current quarter results, where the -$0.03 actual EPS reported on 9/29/2019 surprised by 57.10% or was higher by $0.04 from the estimated -$0.07.

Sales Growth to decline -3.10% for the year

How well will Hi-Crush Inc. perform as a business over the current quarter, year and next 5-year period? Compared to the year-ago quarter, analysts forecast the company to bring in between $133.48M and $165.3M in current quarter sales. The consensus estimated for the current quarter is $148.55M from sales. Forecasts for this fiscal year are between $642M and $674M and the consensus estimate for sales is at $658.15M. HCR has its next quarter sales estimates at between $119.45M and $171M, with the quarter-over-quarter growth estimates at -16.30% and the annual growth forecast for the year at -3.10%.

Who owns shares in Hi-Crush Inc. (HCR)?

Vanguard Group, Inc. (The) tops the list of institutional owners as it is holding 3.46 million shares or 3.43% of shares outstanding. Renaissance Technologies, LLC and Citigroup Inc. held 1.48 million and 921349.0 representing 1.47% and 0.91% respectively at the close of the last trading session. As of Sep 29, 2019, Geode Capital Management, LLC accounted for 703915.0 shares at over 1.22 million. This represented 0.70% of shares outstanding. JP Morgan Chase & Company held 563198.0 shares at over 979964.0 representing 0.56% of shares outstanding.

HCR Insider Activity

On 6/07/2019, by the name Rasmus Robert E bought 100000.0 shares worth $163000.0 at the price of $1.63 per share. Filings also show that Oehlert Michael Alan bought a total of 56000.0 shares on 6/07/2019 valued at $99100.0. Since the last insider activity, the company’s share price has dropped -59.34%.